Health Condition 1: null- Fetal Growth Restriction
Conditions
Interventions
Intervention1: Micronised Allylestrenol (5 mg) tablets: Micronised Allylestrenol (5 mg), 2 tablets twice daily from diagnosis of FGR till 37th completed weeks of gestation or till the preganancy termi
Sponsors
Walter Bushnell Pvt Ltd
Eligibility
Inclusion criteria
Inclusion criteria: 1. Singlenton pregnancy 2. Preganant women from the day of diagnosis of FGR but within 34 completed weeks of gestation 3. Criteria for diagnosis of FGR: Clinical + One parameter of USG (a) Clinical: Discrepancy of at least 4 weeks or more or 4 cm by SFH (Symphysio fundal height) (b) USG: - Abdominal circumference (AC) 2 S.D from mean for gestational age - Amniotic fluid index (AFI) 8 cm - Femur length to abdominal circumference (FL/AC) ratio 24 - Head circumference to abdominal circumference ratio 1 - Estimated Fetal weight 2 S.D from mean for gestational age 3. Written informed consent
Exclusion criteria
Exclusion criteria: 1. Pregnant women aged 18 and 35 years 2. Patients unwilling to give consent 3. Premature rupture of membranes 4. Any congenital anomaly in the fetus detected on USG 5. Patient on any other medication for FGR (Beta-sympathomimetics like Isoxpurine, Ritodrine, Aspirin etc.) 6. Symmetric FGR 7. Women with TORCH infections 8. Multiple pregnancy
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| 1. Gestational age at delivery 2. Birth weight of the baby 3. APGAR scoreTimepoint: 1. Patients will be evaluated every 2 weeks in 8 weeks study period 2. Final outcome at delivery | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Mode of delivery 2. Placental weight 3. NICU admissions 4. Adverse effects of drugsTimepoint: 1. Patients will be evaluated every 2 weeks in 8 weeks study period 2. Final outcome at delivery | — |
Countries
India
Contacts
Public ContactDr Sumita Mehta
Outcome results
None listed